| Followers | 827 |
| Posts | 119535 |
| Boards Moderated | 15 |
| Alias Born | 09/05/2002 |
Friday, November 16, 2007 1:24:36 PM
The COLY buyout dispels two longstanding biotech canards:
Canard #1
Big Pharma won’t pay a large premium to
the market price of a small biotech company.
Fact: PFE is paying a 167% premium to
COLY’s closing price yesterday (i.e. the
buyout price is 267% of yesterday’s close).
Canard #2
News of a biotech buyout always leaks.
Fact: There was no leakage in this case
(see chart below).
Canard #1
Big Pharma won’t pay a large premium to
the market price of a small biotech company.
Fact: PFE is paying a 167% premium to
COLY’s closing price yesterday (i.e. the
buyout price is 267% of yesterday’s close).
Canard #2
News of a biotech buyout always leaks.
Fact: There was no leakage in this case
(see chart below).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
